Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lisa Buford

Physician Assistant Paducah, KY Physician Assistant

NPI 1780600932 CMS profile 10804708

1532 Lone Oak Rd Ste 150, Paducah, KY 42003

Open in the dashboard

General payments

$9,041

507 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Buford of Paducah, KY is reported in the CMS Open Payments database as having received $9,041 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $815 36
2024 General $2,187 22
2023 General $2,950 193
2022 General $2,146 173
2021 General $943 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Buford
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lisa Buford were reported at $815. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lisa Buford Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $943 $132 $37–$438 $132
2022 $2,146 $155 $48–$522 $149
2023 $2,950 $167 $52–$557 $160
2024 $2,187 $178 $55–$600 $164
2025 $815 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Inspire Medical Systems, Inc. $2,303 26 payments
  2. AbbVie, Inc. $1,291 115 payments
  3. Pfizer Inc. $520 52 payments
  4. EMD Serono, Inc. $510 19 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $405 45 payments
  6. Novartis Pharmaceuticals Corporation $351 42 payments
  7. Alexion Pharmaceuticals, Inc. $350 11 payments
  8. Neurocrine Biosciences, Inc. $237 9 payments
  9. Jazz Pharmaceuticals Inc. $215 7 payments
  10. Teva Pharmaceuticals USA, Inc. $184 20 payments
  11. Other $2,676 161 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,558 499 payments
  2. Travel and Lodging $1,279 5 payments
  3. Education $204 3 payments
Products named General payments · program years 2021–2025
  1. INSPIRE $2,303 26 payments
  2. UBRELVY $689 70 payments
  3. NURTEC ODT Primary Care $526 63 payments
  4. NURTEC ODT Pain $504 51 payments
  5. QULIPTA $410 34 payments
  6. INGREZZA $220 8 payments
  7. KESIMPTA Neurology $199 19 payments
  8. MAVENCLAD $186 12 payments
  9. NUEDEXTA $157 9 payments
  10. KESIMPTA Neuroscience $152 23 payments
  11. Other $3,701 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

343

Median for Physician Assistant: 241

Drug cost

$14,740

Median for Physician Assistant: $4,110

Branded share of claims

23%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Namzaric Memantine Hcl/Donepezil Hcl Brand 12 $6,714
Pregabalin Generic 17 $1,586
Ropinirole Hcl Generic 79 $1,377
Entacapone Generic 13 $1,137
Pramipexole Dihydrochloride Pramipexole Di-Hcl Brand 24 $836
Carbidopa-Levodopa Carbidopa/Levodopa Brand 43 $677
Eszopiclone Generic 16 $657
Modafinil Generic 18 $474
Topiramate Generic 36 $447
Primidone Generic 20 $295

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$30,149

Medicare's payments for the services billed

Medicare patients

403

Average age 72

Services billed

642

199 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 45%
Depression 34%
Chronic kidney disease 31%
Ischemic heart disease 30%
COPD 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record